利用多肽偶联疫苗靶向SARS-CoV-2早期生命周期阶段
研究设计多肽偶联疫苗靶向SARS-CoV-2刺突蛋白多个关键结构域,采用iBoost技术在小鼠中诱导针对特定肽段的体液和细胞免疫应答,并对Delta和Omicron变异株产生交叉保护;接种仓鼠攻毒后针对关键肽段产生高抗体水平、早期中和抗体应答,体重下降较对照组少。
要点
- 多肽偶联疫苗靶向刺突蛋白RBM、SD1、SD2、S1/S2、FP+S2'和HR1六个关键结构域。
- 小鼠免疫诱导针对刺突蛋白特定肽段的体液和细胞免疫,并对Delta和Omicron变异株产生交叉保护。
- 接种仓鼠攻毒后针对关键肽段产生高抗体水平、早期中和抗体应答,体重下降较对照组少。
核心结论
- 利用iBoost技术与多肽设计策略可成功靶向刺突蛋白非免疫优势区域,同时激活适应性免疫系统的体液和细胞免疫。
研究设计与样本
- 研究设计多肽偶联疫苗,采用iBoost技术,选取刺突蛋白六个关键结构域肽段序列,并在小鼠中进行免疫研究、在仓鼠中进行攻毒研究。
主要发现
- 小鼠免疫研究显示同时产生针对刺突蛋白特定肽段的靶向体液和细胞免疫应答,并诱导对Delta和Omicron冠状病毒变异株的交叉保护。
- 接种仓鼠攻毒后针对关键肽段产生高抗体水平,诱导早期中和抗体应答,体重下降较对照组少。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The spike glycoprotein is a key factor in the infection cycle of SARS-CoV-2, as it mediates both receptor recognition and membrane fusion by the virus. Therefore, in this study, we aimed to design a multi-peptide conjugate vaccine against SARS-CoV-2, targeting the early stages of the virus's life cycle. We used iBoost technology, which is designed to induce immune responses against low- or non-immunogenic epitopes. We selected six peptide sequences, each representing a key domain of the spike protein (i.e., receptor binding domain (RBM), subdomain 1 (SD1), subdomain 2 (SD2), S1/S2, fusion peptide and the S2' sequences (FP + S2'), heptad repeat 1 (HR1)). Immunization studies in mice displayed targeted humoral and cellular immune responses against specific peptides of the spike protein simultaneously, while inducing cross-protection against the Delta and Omicron coronavirus variants. Moreover, vaccinated hamsters challenged with SARS-CoV-2 elicited high antibody levels against key peptides, induced early neutralizing antibody responses and resulted in less weight loss compared to controls. This highlights the potential for improving viral control and disease outcomes when utilizing this strategy. Therefore, by using iBoost technology in conjunction with our peptide design strategy, we were able to successfully target non-immunodominant regions in the spike protein while activating both arms of the adaptive immune system.
引用
- Myburgh L, Karsjens H, Blanas A, et al. Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine. Vaccine. 2025. PMID: 40088511. doi:10.1016/j.vaccine.2025.126989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。